JP2023549761A5 - - Google Patents

Info

Publication number
JP2023549761A5
JP2023549761A5 JP2023527977A JP2023527977A JP2023549761A5 JP 2023549761 A5 JP2023549761 A5 JP 2023549761A5 JP 2023527977 A JP2023527977 A JP 2023527977A JP 2023527977 A JP2023527977 A JP 2023527977A JP 2023549761 A5 JP2023549761 A5 JP 2023549761A5
Authority
JP
Japan
Prior art keywords
syndrome
disease
protein
nuclear protein
target nuclear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058276 external-priority patent/WO2022099025A1/en
Publication of JP2023549761A publication Critical patent/JP2023549761A/ja
Publication of JP2023549761A5 publication Critical patent/JP2023549761A5/ja
Pending legal-status Critical Current

Links

JP2023527977A 2020-11-06 2021-11-05 核タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Pending JP2023549761A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110616P 2020-11-06 2020-11-06
US63/110,616 2020-11-06
PCT/US2021/058276 WO2022099025A1 (en) 2020-11-06 2021-11-05 Nuclear protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023549761A JP2023549761A (ja) 2023-11-29
JP2023549761A5 true JP2023549761A5 (cg-RX-API-DMAC7.html) 2024-11-08

Family

ID=81456815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527977A Pending JP2023549761A (ja) 2020-11-06 2021-11-05 核タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法

Country Status (7)

Country Link
US (1) US20240026329A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240751A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549761A (cg-RX-API-DMAC7.html)
CN (1) CN117222660A (cg-RX-API-DMAC7.html)
AU (1) AU2021374981A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200977A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022099025A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200980A1 (en) * 2020-11-06 2022-05-12 Flux Therapeutics, Inc. Cytosolic protein targeting engineered deubiquitinases and methods of use thereof
CN116396965B (zh) * 2023-03-01 2024-03-19 北京市心肺血管疾病研究所 Ahdc1在构建肥胖动物模型中的应用及方法和药物筛选方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
GB201714718D0 (en) * 2017-09-13 2017-10-25 Autolus Ltd Cell
EP3706782A4 (en) * 2017-11-06 2021-09-08 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
AU2020224327B2 (en) * 2019-02-21 2022-09-29 Entact Bio Limited Survival-targeting chimeric ( SURTAC) molecules
EP4048316A1 (en) * 2019-10-21 2022-08-31 Translate Bio, Inc. Compositions, methods and uses of messenger rna

Similar Documents

Publication Publication Date Title
KR102533834B1 (ko) 개질된 미토콘드리아 및 이의 용도
ES2871899T3 (es) Péptidos antiinflamatorios y composición que comprende a los mismos
JP2020096630A5 (cg-RX-API-DMAC7.html)
EP1301605B1 (en) Nk cells activating receptors and their therapeutic and diagnostic uses
WO2021213421A1 (zh) 融合蛋白分子及其制备方法和用途
JP2026074003A (ja) B7h3標的タンパク質及びその使用方法
EP1502949B1 (en) Antimicrobial polypeptide and utilization thereof
KR20030048041A (ko) 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인)
AU2001278662A1 (en) NK cells activating receptors and their therapeutic and diagnostic uses
WO2023036246A1 (zh) 一种转基因免疫效应细胞及其应用
CA3180251A1 (en) Cytokine conjugates
US20260132180A1 (en) Oncoselective therapy
WO2017061354A1 (ja) 遺伝子発現用カセット及びその産生物
JP2023548973A5 (cg-RX-API-DMAC7.html)
KR20220007619A (ko) 면역조절 조성물 및 방법
JPH06220099A (ja) 可溶性ldlリセプター
JP2023549167A5 (cg-RX-API-DMAC7.html)
JP6871679B2 (ja) 遺伝子発現用カセット及びその産生物
US20240317831A1 (en) Nk cell engager molecules and methods of use
CN106496329B (zh) 一种含有胶原蛋白结合结构域的融合蛋白
CA3225734A1 (en) Chimeric klebicins
JP2017070224A (ja) 遺伝子発現用カセット及びその産生物
JP2023551068A5 (cg-RX-API-DMAC7.html)
TW202144579A (zh) 病毒載體在冠狀病毒疫苗生產的用途
KR20200069253A (ko) 인간 항-antxr 키메라 항원 수용체 및 이의 용도